iTeos to Participate in Upcoming Investor Conferences
iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical company focused on immuno-oncology therapeutics, has announced its participation in two upcoming investor conferences in September 2024. The company will be present at the Wells Fargo Healthcare Conference on September 4 in Boston, and the Cantor Fitzgerald Global Healthcare Conference on September 18 in New York.
At both events, iTeos management will engage in fireside chats and one-on-one investor meetings. The Wells Fargo conference presentation is scheduled for 4:30 PM ET, while the Cantor Fitzgerald conference presentation will take place at 10:20 AM ET. Interested parties can access live webcasts of the presentations through the Investors section of iTeos' website, with archived replays available for approximately 30 days post-event.
iTeos Therapeutics (Nasdaq: ITOS), un'azienda biofarmaceutica in fase clinica focalizzata su terapie immuno-oncologiche, ha annunciato la sua partecipazione a due conferenze per investitori che si terranno a settembre 2024. L'azienda sarà presente al Wells Fargo Healthcare Conference il 4 settembre a Boston e al Cantor Fitzgerald Global Healthcare Conference il 18 settembre a New York.
In entrambi gli eventi, il management di iTeos parteciperà a dibattiti informali e incontri individuali con gli investitori. La presentazione della conferenza Wells Fargo è programmata per le 16:30 ET, mentre la presentazione della conferenza Cantor Fitzgerald avrà luogo alle 10:20 ET. Le parti interessate possono accedere alle dirette webcast delle presentazioni attraverso la sezione dedicata agli investitori del sito web di iTeos, con repliche archiviate disponibili per circa 30 giorni dopo l'evento.
iTeos Therapeutics (Nasdaq: ITOS), una empresa biofarmacéutica en etapa clínica centrada en terapias de inmuno-oncología, ha anunciado su participación en dos próximas conferencias de inversores en septiembre de 2024. La empresa estará presente en la Wells Fargo Healthcare Conference el 4 de septiembre en Boston y en la Cantor Fitzgerald Global Healthcare Conference el 18 de septiembre en Nueva York.
En ambos eventos, la dirección de iTeos participará en charlas informales y reuniones individuales con inversores. La presentación en la conferencia de Wells Fargo está programada para las 4:30 PM ET, mientras que la presentación en la conferencia de Cantor Fitzgerald se llevará a cabo a las 10:20 AM ET. Las partes interesadas pueden acceder a las transmisiones en vivo de las presentaciones a través de la sección de Inversores del sitio web de iTeos, con repeticiones archivadas disponibles durante aproximadamente 30 días después del evento.
iTeos Therapeutics (Nasdaq: ITOS), 면역종양학 치료제에 주력하는 임상 단계의 생명공학 기업이 2024년 9월에 열리는 두 개의 투자자 회의에 참가한다고 발표했습니다. 이 회사는 9월 4일 보스턴에서 열리는 웰스파고 헬스케어 컨퍼런스와 9월 18일 뉴욕에서 열리는 칸토르 피츠제럴드 글로벌 헬스케어 컨퍼런스에 참석할 예정입니다.
두 행사에서 iTeos 경영진은 비공식적인 대화와 일대일 투자자 회의에 참여합니다. 웰스파고 회의의 발표는 동부 표준시 기준으로 오후 4시 30분에 예정되어 있으며, 칸토르 피츠제럴드 회의의 발표는 오전 10시 20분에 진행됩니다. 관심 있는 분들은 iTeos 웹사이트의 투자자 섹션을 통해 발표의 생중계를 시청할 수 있으며, 이벤트 후 약 30일 동안 다시 청취할 수 있는 아카이브가 제공됩니다.
iTeos Therapeutics (Nasdaq: ITOS), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies en immuno-oncologie, a annoncé sa participation à deux conférences d'investisseurs à venir en septembre 2024. L'entreprise sera présente à la Wells Fargo Healthcare Conference le 4 septembre à Boston et à la Cantor Fitzgerald Global Healthcare Conference le 18 septembre à New York.
Lors de ces deux événements, la direction d'iTeos participera à des discussions informelles et à des réunions individuelles avec des investisseurs. La présentation de la conférence Wells Fargo est prévue à 16h30 ET, tandis que celle de la conférence Cantor Fitzgerald se tiendra à 10h20 ET. Les parties intéressées peuvent accéder aux webdiffusions en direct des présentations via la section Investisseurs du site Web d'iTeos, avec des rediffusions archivées disponibles pendant environ 30 jours après l'événement.
iTeos Therapeutics (Nasdaq: ITOS), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf immunonkologische Therapeutika konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben. Das Unternehmen wird am 4. September in Boston bei der Wells Fargo Healthcare Conference und am 18. September in New York bei der Cantor Fitzgerald Global Healthcare Conference anwesend sein.
Bei beiden Veranstaltungen wird das Management von iTeos an Informellen Gesprächen und Eins-zu-eins-Investorenmeetings teilnehmen. Die Präsentation der Wells Fargo-Konferenz ist für 16:30 Uhr ET geplant, während die Präsentation der Cantor Fitzgerald-Konferenz um 10:20 Uhr ET stattfinden wird. Interessierte Parteien können die Live-Webcasts der Präsentationen über den Bereich für Investoren auf der iTeos-Website abrufen, wobei Archiv-Wiedergaben etwa 30 Tage nach der Veranstaltung verfügbar sind.
- None.
- None.
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September:
2024 Wells Fargo Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, September 4, 2024
Time: 4:30 PM ET
Location: Boston, M.A.
Cantor Fitzgerald Global Healthcare Conference
Format: Fireside chat and one-on-one meetings
Date: Wednesday, September 18, 2024
Time: 10:20 AM ET
Location: New York, N.Y.
A live webcast of the conference presentation will be available on the Investors section of the company’s website at www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
FAQ
What investor conferences will iTeos Therapeutics (ITOS) attend in September 2024?
When and where is iTeos Therapeutics (ITOS) presenting at the Wells Fargo Healthcare Conference?
What is the format of iTeos Therapeutics' (ITOS) participation in the September 2024 investor conferences?
How can investors access iTeos Therapeutics' (ITOS) conference presentations in September 2024?
